Innovative respiratory inhaler Airflusal® Forspiro® receives Alufoil Trophy 2015

April 16, 2015 – AirFluSal® Forspiro®, an innovative respiratory inhaler from Sandoz, has won the coveted Alufoil Trophy 2015 in the Product Preservation category. The inhaler uses a specially designed alufoil blister strip, which was developed by Amcor Flexibles, that ensures a longer shelf life of the inhalation powder.

This recognition for technical innovation is the second award for AirFluSal® Forspiro®. In 2011, the device received the Red Dot Product Design Award, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in …

/by

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz launches authorized generic version of EXFORGE® in the US

Princeton, New Jersey, March 31, 2015 – Sandoz today announced the US market introduction of amlodipine and valsartan combination tablets, a generic version of EXFORGE® made by Novartis.

Amlodipine and valsartan tablets are a combination of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB).

Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure:

  • in patients not adequately controlled on monotherapy with a DHP CCB or an ARB
  • …
/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

Sandoz receives approvals in Ireland and Sandoz launches innovative respiratory inhaler AirFluSal® Forspiro® in Portugal and Ireland

  • Sandoz launches 50-250 and 50-500µg dosage forms in Portugal and Ireland
  • Innovative inhaler offers asthma and COPD patients a new therapeutic option
  • Now available to patients in 14 countries, as global roll-out continues apace

Holzkirchen, March 11, 2015 – Sandoz today announces the launch of AirFluSal® Forspiro®, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal, which was first approved in Denmark, has now been launched in a …

/by

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

  • Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA
  • Zarxio is approved for all indications included in the reference product’s (NEUPOGEN®) label
  • Approval paves way for greater access to high-quality biologics in the US and underscores Sandoz global leadership in biosimilars

Holzkirchen, March 06, 2015 – Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved ZarxioTM (filgrastim-sndz) for all …

/by

FDA approves first biosimilar Zarxio™ (filgrastim-sndz) from Sandoz

  • Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA
  • Zarxio is approved for all indications included in the reference product’s (NEUPOGEN®) label
  • Approval paves way for greater access to high-quality biologics in the US and underscores Sandoz global leadership in biosimilars

Holzkirchen, March 06, 2015 – Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved ZarxioTM (filgrastim-sndz) for all …

/by

Sandoz announces training program for midwives in Ethiopia, to reduce maternal and newborn mortality

  • Approximately 400 mothers and newborns die in Ethiopia each day1,2 partly due to health workers’ limited knowledge in the area of obstetrics
  • Enhancing medical knowledge and skills of health workers helps reduce maternal and newborn mortality
  • Sandoz is committed to increasing access to high-quality, affordable medicines, as well as healthcare services and education for mothers and children

Holzkirchen, Germany, March 2, 2015 – Sandoz today announced the launch of a new program, New Life & New Hope, to improve maternal and …

/by

Novartis announces completion of transactions with GSK

  • Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business
  • Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics
  • Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small molecules, positioning Novartis as a preferred partner for combination agents
  • Transactions expected to immediately lift core margins and further support overall …
/by

On World Cancer Day, Sandoz highlights global problem of child cancer

February 04, 2015 – Between 160,000 and 200,000 children are estimated to be diagnosed with childhood cancer and around 100,000 die from it each year. With proper diagnosis, treatment and drugs, most childhood cancers can be cured. In the developed countries, 80% of children survive, which is a great achievement in oncology treatment. However, in middle and low income countries, survival is estimated to drop to as low as 5%. Cancer is a leading cause of childhood deaths in these countries. This disparity is primarily because of lack of proper diagnosis and basic treatment …

/by